Erschienen in:
08.05.2023 | Correction
Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
verfasst von:
Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Haruka Ochi, Shino Ohsawa, Annabelle Ayame Okada, on behalf of TENAYA and LUCERNE Investigators
Erschienen in:
Japanese Journal of Ophthalmology
|
Ausgabe 3/2023
Einloggen, um Zugang zu erhalten
Excerpt
In the original publication, incorrect Supplementary Material has been published. The original publication has been updated with correct Supplementary Material. …